> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for Horizon’s Tepezza
- URL: https://www.fdaweb.com/regulatory-review-period-for-horizons-tepezza/
- Published: 2022-06-30T12:00:00.000Z
- Updated: 2026-09-14T17:50:45.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5152211

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Horizon Therapeutics’ Tepezza (teprotumumab-trbw), indicated for treating thyroid eye disease. The review period is 2,958 days, of which 2,760 days occurred during the testing phase and 198 days occurred during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-06-30/pdf/2022-13956.pdf?ref=fdaweb.com).